(NASDAQ: DYN) Dyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.
Dyne Therapeutics's earnings in 2026 is -$446,214,000.On average, 17 Wall Street analysts forecast DYN's earnings for 2026 to be -$543,995,395, with the lowest DYN earnings forecast at -$698,658,811, and the highest DYN earnings forecast at -$402,006,062. On average, 12 Wall Street analysts forecast DYN's earnings for 2027 to be -$502,028,999, with the lowest DYN earnings forecast at -$774,670,302, and the highest DYN earnings forecast at -$285,909,484.
In 2028, DYN is forecast to generate -$331,357,952 in earnings, with the lowest earnings forecast at -$862,002,653 and the highest earnings forecast at $100,501,515.